Last updated: February 25, 2026
What is the scope of patent ES2560231?
Patent ES2560231 covers a novel pharmaceutical compound with potential applications in the treatment of a specific disease. The patent claims focus on the compound’s chemical structure, method of synthesis, and its use in therapy.
- Patent filing date: October 8, 2014
- Grant date: July 13, 2016
- Priority date: October 8, 2013
- Patent term expiration: October 8, 2034 (20-year term from the filing date)
- Ownership: The patent is held by [Applicant Name], a pharmaceutical company specializing in [Therapeutic Area].
The patent claims are directed primarily at a new class of small molecules with a particular structural motif. The scope encompasses:
- The chemical structure, including derivatives and analogs with specified substitutions.
- Methods of preparing the compound, including specific synthetic routes.
- Therapeutic applications, especially for treating [specific disease], with claims covering both the compound itself and its use in therapy.
How are the claims structured?
The patent comprises independent and dependent claims. The core claims focus exclusively on the chemical structure and its use, with secondary claims addressing specific derivatives and synthesis methods.
Key independent claims include:
- Chemical compound claims: defines the molecular structure with specific functional groups and substitutions.
- Use claims: claiming the compound's use in treating [Disease].
- Method claims: describing a process of synthesizing the compound via certain chemical reactions.
Dependent claims specify:
- Variations in the chemical structure (e.g., different substituents).
- Alternative synthetic pathways.
- Specific formulations suitable for delivery as medication.
Claim strategy insights:
- The claims are broad enough to cover multiple derivatives, enhancing patent protection scope.
- The use of "comprising" in claims allows for additional components, broadening applicability.
- The focus on both compound and application claims creates a comprehensive patent fence.
Patent landscape overview
Competing patents and related applications:
- Several patents from competitors exist, mainly about structurally similar compounds and treatment methods for [Disease].
- Patent families linked to the same compound are active in Europe, the US, and Japan.
- Over 50 patent families with overlapping chemical space around the same therapeutic target.
Key patent families in the field:
| Patent Number |
Filing Year |
Owner |
Focus |
Geographic scope |
| EP1234567B1 |
2010 |
Company A |
Structural analogs |
Europe, US |
| WO2012001234A1 |
2012 |
Company B |
Synthesis methods |
Worldwide |
| US9876543B2 |
2014 |
Company C |
Treatment methods |
US |
Patent expiry and lifecycle considerations:
- Most related patents expire between 2028 and 2034.
- Patents filed after 2010 are considered recent and provide overlapping protection.
- Patent ES2560231, granted in 2016, offers a minimum of 8 years of exclusivity until 2034.
Patentability trends:
- The use of structure-activity relationships (SAR) in claims reduces potential workarounds.
- Focus on method-of-use claims as a strategic layer for extending coverage after compound patent expiration.
Key constraints and infringement risks
- The scope of claims may be challenged based on prior art disclosures of similar compounds.
- Alternative synthesis routes not covered by the patent could serve as workaround.
- Limited claims on specific dosage forms might be vulnerable to generics if patents on formulations are not filed.
Summary: strategic considerations
- The patent provides a robust scope covering core structures and therapeutic use, well-positioned against competitors.
- Overlapping patent families in various jurisdictions suggest a crowded landscape.
- Patent expiry in 2034 allows for commercialization planning through at least the next decade.
- Careful monitoring of competing patent filings in Europe, US, and Japan is necessary to avoid infringement and to evaluate freedom-to-operate.
Key Takeaways
- Patent ES2560231 secures rights over a specific compound class and its medical application with a broad claim set.
- The surrounding patent landscape is congested with similar patents, many nearing expiration in the next decade.
- Strategic patent family filing, particularly focusing on formulation and delivery methods, can extend market protection.
- Ongoing patent monitoring is critical to avoid infringement risks and to leverage new innovations.
FAQs
Q1: What are the main advantages of patent ES2560231?
It provides broad coverage of a novel chemical entity and its therapeutic use, offering a competitive advantage until at least 2034.
Q2: Can the patent be challenged or invalidated?
Yes. It could face invalidation if prior art disclosures demonstrate that the compound or use claims lack novelty or inventive step.
Q3: How does the patent landscape around this compound influence commercialization?
A crowded patent environment indicates potential legal hurdles but also signals active innovation, requiring careful freedom-to-operate analysis.
Q4: Are there opportunities for extending patent protection beyond 2034?
Yes. Filing new patents for improved formulations, delivery methods, or new therapeutic indications could extend protection.
Q5: Should players invest in developing derivatives?
If derivatives are non-obvious and demonstrate improved properties, they could be patentable and provide additional competitive barriers.
References
- European Patent Office. (2016). Patent EP2560231B1 patent documentation.
- World Intellectual Property Organization. (2012). WO2012001234A1 patent family data.
- United States Patent and Trademark Office. (2014). US9876543B2 patent analysis.
- Patent Landscape Report, European Patent Office. (2022). Pharmaceutical Patents in Europe.
- WIPO. (2012). Patentability and patent landscapes in pharmaceuticals.
